作为可能的抗癌增强剂在多塞塔克塞尔治疗前列腺癌细胞中的
Ingvar Holm1, Bodil Hernroth2,3, Amanda Rosander2
1Department of Science, Mathematics and Society, Malmö University, Malmö, Sweden.
Anticancer research
|February 29, 2024
概括
(Mn) 与多塞 (DOC) 结合,可以增强前列腺癌细胞死亡. 这种组合可能会降低多塞塔塞尔的剂量,可能会降低治疗副作用对割抵抗性前列腺癌患者.
科学领域:
- 在瘤学瘤学.
- 癌症研究 癌症研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗割前列腺癌 (CRPC) 是一个重大的临床挑战.
- 多西 (DOC) 是CRPC的关键化疗剂,但治疗耐药性很常见.
研究的目的:
- 研究 (Mn) 在治疗前列腺癌中增强多塞 (DOC) 疗效的潜力.
- 评估和DOC对前列腺癌细胞活力和毒性的联合作用.
主要方法:
- 前列腺癌细胞 (PC3) 用不同剂量和持续时间的DOC和Mn单独和组合治疗.
- 治疗48小时后评估了细胞活力,细胞毒性,细胞循环进展和亡蛋白水平.
主要成果:
- 联合Mn和DOC显著增强了抑制前列腺癌细胞活力的作用.
- 在较低度时,Mn减轻了DOC诱导的毒性,在较高度时,诱导了非亡细胞死亡途径.
- 蛋白质分析揭示了Mn在补偿死亡受体抑制和调节细胞死亡机制方面的作用.
结论:
- 多塞和的组合显示出改善CRPC治疗结果的前景.
- 这种协同作用的方法可能可以减少多塞塔塞尔剂量,从而最大限度地减少相关的副作用.
关键词:
在PC3中,PC3是PC3.灭症 (apoptosis) 是一种死亡的过程.细胞循环中的细胞循环.细胞活力的细胞活力.多塞塔克塞尔 (Docetaxel) 是一种药物.酸是一种酸.毒性的毒性 毒性的毒性更多相关视频
06:02Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
7.6K
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.7K
相关概念视频
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Electron Transport Chain: Complex I and II
13.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
